Medico Remedies bags Rs 73 crore drug supply order from UP govt

Govt Defence OrderBusiness Updates View source PDF Explain this filing

MEDICO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.2%Reaction day

₹47.45

prior close

₹49.18

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-2.7%+3.8% vs market

Pharmaceuticals peers, median of 157sector-2.1%+3.3% vs sector

On the reaction day the stock moved 3.8 pts more than Nifty Microcap 250 and 3.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.4

10m

-1.6

15m

-0.3

30m

-0.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.2-2.7+3.8-2.1+3.3

Next day

-5.2-3.5-1.7-3.4-1.8

+3.9-2.0+5.9-2.0+5.9

+8.6-4.1+12.6-3.4+11.9

+8.7-3.9+12.7-3.5+12.3

+3.2-2.0+5.1-3.2+6.4

+5.9-0.6+6.5-2.2+8.1

15d

+1.8+4.4-2.6+1.0+0.8

-3.1+1.3-4.4-1.5-1.6

-19.9-6.9-13.1-7.9-12.1

-14.4+4.6-19.1-0.1-14.3

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Medico Remedies Limited has secured a government supply order worth Rs 73.23 crore from Uttar Pradesh Medical Supplies Corporation Limited, a Government of UP entity, to supply Azithromycin 500mg tablets. The company must complete the full supply by 31 October 2026. This is a domestic order with no related party interest. The buyer handles centralized purchase and distribution of medicines and health supplies for the UP government.

Likely market impact

Significant order from a state government body boosts order book and provides revenue visibility through Oct 2026 for the pharma company.